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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was
requested by the European Commission according to Art. 29 1(a) of the Regulation (EC) No 178/2002
to carry out a review of existing literature on the safety of ethyl acrylate [FL-no: 09.037] when used as
a ﬂavouring substance. Ethyl acrylate [FL-no: 09.037] was evaluated in 2010 by EFSA in FGE.71 as a
ﬂavouring substance, based on the 2006 JECFA evaluation. The Panel concluded that ethyl acrylate
was of no safety concern at estimated level of intake as ﬂavouring substance based on the Maximised
Survey-Derived Daily Intake (MSDI) approach. The Panel has evaluated the new literature available
and any previous assessments performed by JECFA (2006) and EFSA (2010). Moreover, new data on
the use levels of ethyl acrylate as ﬂavouring substance have been provided. For use as ﬂavouring
substance, the chronic dietary exposure estimated using the added portions exposure technique
(APET), is calculated to be 3,545 lg/person per day for a 60-kg adult and 2,233 lg/person per day for
a 15-kg 3-year-old child. Exposure from food contact materials may be up to 6,000 lg/person per day.
The Panel considered that based on the available data, which covers all relevant genetic endpoints
(i.e. gene mutations, structural and numerical chromosomal aberrations) there is no concern with
respect to genotoxicity of ethyl acrylate. The Panel evaluated the available carcinogenicity studies
conducted in rats and mice and agreed with the NTP evaluation (1998) concluding that the
forestomach squamous cell papilloma and carcinoma observed in rodents were not relevant to
humans. Additionally, there was no evidence of systemic toxicity in short-term and subchronic toxicity
studies. Therefore, the Panel concluded that there is no safety concern for the use of ethyl acrylate as
a ﬂavouring substance, under the intended conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122.
The substance benzophenone, [FL no. 07.032] (CAS No. 119-61-9) is currently included in this
Union List. It is a substance which is not currently under evaluation. This substance is also known as
diphenyl ketone. This substance was included in the Union list on the basis of the EFSA evaluation in
FGE 69 of 2008. FGE 69 includes this substance. Benzophenone was evaluated by JECFA as a
ﬂavouring substance, with JECFA no. 831. The studies evaluated by IARC were not considered in the
EFSA opinion on FGE 69. There may be also additional studies on the safety of this substance.
The substance ethyl acrylate, [FL no. 09.037], (CAS No. 140-88-5) was included in the Union list on
the basis of the EFSA evaluation in FGE 71 of 2010. FGE.71 includes this substance. Ethyl acrylate was
evaluated by JECFA as a ﬂavouring substance, with JECFA no. 1351. The studies evaluated by IARC
were not considered in the EFSA opinion of FGE.71. There may be also additional studies on the safety
of this substance.
1.1.2. Terms of Reference
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/20023, the European Commission
requests the European Food Safety Authority (EFSA) to carry out a review of existing published literature
on the safety of the ﬂavouring substances benzophenone, [FL. No 07.032], (CAS No. 119-61-9) and
ethyl acrylate, [FL 09.037], (CAS No. 140-88-5), and advise on their safety when used as ﬂavouring
substances.
1.2. Interpretation of the Terms of Reference
Since benzophenone [FL- no: 07.032] and ethyl acrylate [FL-no: 09.037] are not structurally related
and were evaluated in different FGEs (FGE.69 and FGE.71), they will be evaluated in separate
opinions. The present document will address the question of the Commission on ethyl acrylate.
Meanwhile, EFSA has also received information on use levels which will be taken into consideration.
Considering the Term of Reference, the Panel will not address in this assessment, the exposure that
may result from the use as food contact material.
In respect to the approach to be followed for the assessment of ethyl acrylate used as a ﬂavouring
substance, the Panel was of the view that previous assessments should be used as starting points for
this scientiﬁc opinion. The previous assessment will be updated with new information that is connected
to the concerns identiﬁed in the background (Section 1.1).
In the background (Section 1.1), it is mentioned that the studies evaluated by IARC in the report
from 1999 on carcinogenicity of ethyl acrylate were not considered in the EFSA evaluation from 2010,
and that there may be additional studies on the safety of ethyl acrylate when used as a ﬂavouring
substance. Thus, the present evaluation is mainly focusing on the genotoxicity and carcinogenicity of
ethyl acrylate, in addition to considering any new data on toxicity, which may have an impact on the
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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safety assessment of ethyl acrylate as ﬂavouring. Moreover, previous assessments of ethyl acrylate by
JECFA (2006) and EFSA (EFSA CEF Panel, 2010a) are brieﬂy presented.
According to the request from the Commission (Section 1.1), the present evaluation will be based
on available data on ethyl acrylate. Acrylic acid is a metabolite of ethyl acrylate and in that sense also
the safety of acrylic acid is included in this evaluation. However, the safety of exposure directly to
acrylic acid will not be evaluated in the present opinion, which according to the terms of reference will
address the use of ethyl acrylate as a ﬂavouring substance.
2. Data and methodologies
The search for literature was done by EFSA on ethyl acrylate [FL-no: 09.037] to review existing
literature on the safety of this substance and to advise on its safety when used as ﬂavouring
substance. A literature search was carried out through Web of Science database until August 2017,
using keywords “ethyl acrylate” or “140-88-5” and “genotox*”, “canc*”, “carc*”, “tumor*”, “toxicokin*”,
“metabol*”, “absorb*”, “distrib*”, “excret*”, and “reproduct*” while searching in “all databases”.
Additional searches were carried out through Scopus database, using the keyword combination of
“ethyl acrylate” and “tox”, and the database of Decernis, using the keyword “140-88-5”.
3. Procedure of the safety assessment
3.1. Assessment
The Panel considered studies already evaluated (JECFA, 2006; EFSA CEF Panel, 2010a) and
additional studies from literature search. Except for genotoxicity, no new relevant studies were
identiﬁed for short-term toxicity, chronic toxicity and carcinogenicity.
3.2. Technical data
Information on the identity of the substance and speciﬁcations are based on data already described
in FGE.71 (EFSA CEF Panel, 2010a) and are presented in Table 1.
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Table 1: Summary of speciﬁcations for the substance ethyl acrylate (EFSA CEF Panel, 2010a)
FL-no
JECFA-no
EU Register
name
Structural
formula
FEMA no
CoE no
CAS no
Phys. Form
Mol. Formula
Mol. weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec. gravity(e)
09.037
1351
Ethyl acrylate 2418
245
140-88-5
Liquid
C5H8O2
100.12
Slightly Soluble
Soluble
99–101
IR
97%
1.403–1.409
0.916–0.919
FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract
Service; ID: Identity; IR: infrared spectroscopy.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
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3.3. Information on existing evaluations from EFSA
Ethyl acrylate [FL-no: 09.037] has been evaluated by JECFA (2006), EFSA considered this
evaluation and concluded, in FGE.71, that ethyl acrylate is of no safety concern at estimated level of
intake as ﬂavouring substance based on the Maximised Survey-Derived Daily Intake (MSDI) approach
(EFSA CEF Panel, 2010a).
Ethyl acrylate was evaluated as a substance in food contact materials (FCM) by the Scientiﬁc
Committee for food (SCF, 1999). They established a group temporary tolerable daily intake (TDI) of
0.1 mg/kg body weight (bw) for several acrylates, expressed as acrylic acid. The temporary TDI was
based on data from experimental animals exposed to acrylic acid. Based on this TDI, a speciﬁc
migration limit (SML) of 6 mg/kg of food was calculated for the group of substances that share acrylic
acid as a common metabolite/degradation product.
In Regulation (EU) No 10/20114, ethyl acrylate is an approved monomer for use in FCM with a
group SML for the sum of substances that have acrylic acid as a common metabolite/degradation
product of 6 mg/kg of food.
3.4. Exposure
3.4.1. Concentration in processed and non-processed foods from natural sources
Ethyl acrylate [FL-no: 09.037] has been reported to occur in passion fruit, pineapple, Beaufort
cheese and durian (IARC, 1999a, Triskelion, 2017). Quantitative data are reported for ethyl acrylate in
pineapple (0.01 mg/kg) (Triskelion, 2017).
3.4.2. Chronic dietary exposure
The exposure assessment to be used in the Procedure for the safety evaluation of the candidate
substance is the chronic added portions exposure technique (APET) estimate (EFSA CEF Panel, 2010b).
The chronic APET for ethyl acrylate has been calculated for adults and children (see Table 2 and
Appendix C). The chronic APET calculation is based on the combined normal occurrence level.
The Panel noted that the contribution from natural occurrence of ethyl acrylate to the APET is
negligible compared to the added ﬂavouring substance.
The Panel noted that exposure to ethyl acrylate may also occur from FCM (SML 6 mg/kg food, as
acrylic acid, corresponding to a maximum exposure of 6 mg/person per day; see Section 3.3).
3.4.3. Acute dietary exposure
Acute exposure is not evaluated, because this opinion addresses only chronic exposure.
Table 2: APET – Chronic dietary exposure
Chronic APET
Added(a) Other dietary sources(b) Combined(c)
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
Adults(d) 59.1 3,545 0.23 14.0 59.1 3,545
Children(e) 149 2,233 0.59 8.85 149 2,233
APET: added portions exposure technique; bw: body weight.
(a): APET Added is calculated on the basis of the normal amount of ﬂavour added to a speciﬁc food category.
(b): APET Other Dietary Sources is calculated based on the natural occurrence of the ﬂavouring in a speciﬁed food category.
(c): APET Combined is calculated based on the combined amount of added ﬂavouring and naturally occurring ﬂavouring in a
speciﬁed food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year old child with a 15 kg bw is considered representative.
4 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact
with food. OJ L 12, 15.1.2011, p. 1–89.
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3.5. Biological and toxicological data
The toxicity of ethyl acrylate has been evaluated by JECFA in 2006 and concerning genotoxicity by
EFSA (EFSA CEF Panel, 2010a). The carcinogenicity was evaluated by IARC in 1999a. Brief summaries
of the previous evaluations will follow below and data not previously considered will be presented.
3.6. Absorption, distribution, metabolism and excretion
Ethyl acrylate is the ethyl ester of acrylic acid. Aliphatic esters formed from 2-alkenoic acids are
generally rapidly hydrolysed to respective alcohols and carboxylic acids by carboxylesterases. Thus,
ethyl acrylate is hydrolysed to acrylic acid and ethanol, which will participate in biochemical pathways,
including the fatty acid pathway and tricarboxylic acid cycle (see review by JECFA, 2006).
In vitro studies
Miller et al. (1981) compared the rate of hydrolysis of ethyl acrylate in homogenates of different
tissues and found the highest rate in liver, followed by whole blood, lung and kidney. In the liver
homogenate, the hydrolysis rate of ethyl acrylate was 26.8 nmol/min. Potter and Tran (1992)
demonstrated that ethyl acrylate reacts with both glutathione (GSH) and protein in vitro.
In vivo studies
14C-Ethyl acrylate has been used for metabolic studies (DeBethizy et al., 1987). Rats were
administered single oral doses of 2, 20 and 200 mg/kg bw and radioactivity was followed during 72 h.
A rapid and high absorption was demonstrated and most of the radioactivity was exhaled as CO2
(52–62% of dosed radioactivity) and almost all during the ﬁrst 10 h after administration. The detection
of 3-hydroxypropionic acid as a urinary metabolite led to the suggestion by the authors, that acrylic
acid was incorporated into propionic acid metabolism, explaining the rapid formation of carbon dioxide.
In urine two metabolites derived from GSH conjugation were also detected. At the two lower doses of
ethyl acrylate, non-protein sulfhydryl (NPSH) content decreased signiﬁcantly at the dosing site,
forestomach and glandular stomach, but not in the liver. NPSH, mainly GSH, cysteine, coenzyme A and
other thiols in the gastric mucosa, are suggested to play an important role in the protection of gastric
mucosa against chemically-induced lesions (Nagy et al., 2007).
Oral dosing of rats with ethyl acrylate was performed in a study by Frederick et al. (1992) to
validate a physiologically based pharmacokinetic and pharmacodynamics model for ethyl acrylate. The
predicted very rapid metabolism was veriﬁed and consistent with the ﬁnding that no ethyl acrylate
could be detected in tissues. The model also predicted glutathione depletion in forestomach.
Overall, ethyl acrylate is rapidly absorbed, metabolised, incorporated into endogenous biochemical
pathways and excreted.
3.6.1. Short-term and subchronic toxicity
A single dose of 100, 200 or 400 mg/kg bw ethyl acrylate administered by gavage to F344 rats
caused mucosal and submucosal oedema and vacuolisation of the tunica muscularis in the forestomach
and mild submucosal oedema in the glandular stomach (Ghanayem et al., 1985). No gastric effects
were observed after equivalent subcutaneous or intraperitoneal (i.p.) doses. After 2 or 4 consecutive
daily doses of 200 mg/kg bw similar effects were observed, and in addition submucosal inﬂammation,
mucosal erosions or ulcers in both portions of the stomach. There was no systemic toxicity. The same
authors (Ghanayem et al., 1986) also studied the recovery of the lesions in rats after 14 daily gavage
doses of 100 or 200 mg/kg bw ethyl acrylate. After 14 days of exposure, the glandular stomach was
normal in all animals and appeared to have adapted to resist the toxicity of ethyl acrylate. The
forestomach exhibited dose-dependent lesions, which were recovered in the low dose group at
14 days following the last dose, while in the high dose group mucosal hyperplasia was still present in
the forestomach at 4 weeks after last exposure.
Male F344/N rats were dosed with ethyl acrylate either by gavage at doses from 2 to 200 mg/kg
bw daily for 2 weeks or via drinking water at concentrations from 200 to 4,000 mg/L (corresponding
to 23–369 mg/kg bw/day, according to the authors) (Frederick et al., 1990). A dose-dependent
increase in irritation of the forestomach was observed in the animals dosed by gavage, while the
animals dosed via drinking water had a much lower incidence and less severe lesions at the
corresponding dose levels. There were no lesions in the glandular stomach. Severe depletion of NPSH
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was observed in the forestomach at gavage doses ≥ 100 mg/kg bw, while no signiﬁcant depletion was
seen after administration via drinking water. The NPSH depletion in glandular stomach and liver were
lower, and not at levels generally associated with toxicity. The authors suggested that the depletion of
NPSH in the rat forestomach was causally related to the histopathology observed at relatively high
doses. Thus, at doses of 100 mg/kg bw per day or greater by gavage, the NPSH content was severely
depleted (below 25% of the initial concentration) and moderate to marked hyperplasia was observed
together with ulceration and erosion of the forestomach epithelium. Minimal depletion of NPSH,
producing minimal to mild hyperplasia, was reported at 20–50 mg/kg bw. At 10 mg/kg bw and less,
no signiﬁcant NPSH depletion and no histopathological ﬁndings were reported.
To design the 2-year carcinogenesis study on ethyl acrylate, the NTP performed several 14-day and
13-week gavage studies in B6C3F1 mice and F344/N rats (NTP, 1986). The principal toxic effect in the
14-day studies was in the forestomach of both sexes in mice and rats. There was no evidence of
systemic toxicity. The lowest dose where histological lesions in the forestomach were detected was
400 mg/kg bw in rats and 200 mg/kg bw in mice.
Sustainability of forestomach hyperplasia was studied in rats treated with ethyl acrylate for
13 weeks with gavage doses of 100 or 200 mg/kg bw per day (Ghanayem et al., 1991). Severe
hyperplasia of the forestomach was observed after 13 weeks. No effects were detected in the
glandular stomach or liver. A signiﬁcant decline in incidence and severity of the hyperplasia was
reported in rats after a recovery period of 8 weeks without treatment and a further decline in effects
were seen after 13 weeks.
Overall, severe irritation of the forestomach and mild oedema of the glandular stomach resulted
from a single dose of ethyl acrylate, administered by gavage. In short-term and subchronic gavage
studies, histological lesions were observed in the forestomach but not in the glandular stomach. The
histopathological lesions in the forestomach were associated to NPSH depletion. After cessation of
exposure, there was a dose-dependent recovery of the forestomach lesions. Exposure of ethyl acrylate
via drinking water caused lower incidence and less severe forestomach lesions. No gastric effects were
observed after parenteral administrations. There was no evidence of systemic toxicity.
3.6.2. Genotoxicity
Summary of in vitro data assessed in FGE.71
In vitro genotoxicity studies described below were considered in FGE.71 (EFSA CEF Panel, 2010a),
based on JECFA evaluation (2006) and are summarised in Appendix A, Table A.1.
Negative results were reported in Ames assays when Salmonella Typhimurium strains (TA97, TA98,
TA100, TA1535, TA1537 and TA1538) were incubated with ethyl acrylate [FL-no: 09.037] at
concentrations up to 10,000 lg/plate (Ishidate et al., 1981; Waegemaekers and Bensink, 1984;
Tennant et al., 1987; Zeiger et al., 1992).
No evidence of mitotic chromosomal loss was obtained when ethyl acrylate at concentrations up to
1,095 lg/mL was incubated with Saccharomyces cerevisiae strain D61.M. Under a cold shock regimen,
evidence of mitotic recombination was reported (Zimmermann and Mohr, 1992).
In the standard assay for forward mutation in mouse lymphoma cells, ethyl acrylate gave uniformly
positive results in the absence of metabolic activation when tested with mouse lymphoma L5178Y Tk+
cells at cytotoxic concentrations (37.5–50 lg/mL) associated with a reduction of the relative total growth
by 50–60% (Tennant et al., 1987; McGregor et al., 1988; Moore et al., 1988; Ciaccio et al., 1998). In
assays for clastogenicity, ethyl acrylate elicited increases in sister chromatid exchanges (SCE) and
chromosomal aberrations (CA) in Chinese hamster ovary (CHO) cells with metabolic activation, but
showed no evidence of clastogenicity in the absence of metabolic activation (Loveday et al., 1990). The
clastogenic potential was unaffected by changes in harvest time (Loveday et al., 1990). Ethyl acrylate
induced an increase in SCE and CA in mouse lymphoma cells in a dose-dependent manner, beginning at
20 lg/mL, in the absence of metabolic activation (Moore et al., 1988). An increase in SCE and CA in CHO
cells was also reported in another study with ethyl acrylate at concentrations of 150 and 299 lg/mL,
respectively, with metabolic activation (Tennant et al., 1987). There was no evidence of clastogenicity in
the absence of metabolic activation (Tennant et al., 1987). Increases in CA were reported at 9.8 lg/mL
in Chinese hamster cells with or without metabolic activation (Ishidate et al., 1981).
In vitro data not previously considered
In vitro genotoxicity studies, previously not considered in the EFSA evaluation are summarised in
Appendix B, Table B.1.
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Ethyl acrylate tested up to 5,000 lg/plate was negative in S. Typhimurium strain TA102 (Kirkland
et al., 2016).
Ethyl acrylate tested up to 2,000 lg/plate in the S. Typhimurium strain YG7108 (ogt, ada)
(mutant of TA1535 strain deﬁcient in methyl transferase), transformed with the plasmid pin3ERb5,
encoding for a complete electron transport chain, comprising P450 reductase, cytochrome b5 and
cytochrome P450 2E1, did not induce any signiﬁcant increase of the revertants (Emmert et al., 2006).
A number of studies are available on in vitro micronucleus (MN) assay in different rodent (V79,
CHL, CHO and L5178Y) and human cell lines, p53 competent and p53 mutated, in the presence and
absence of cytochalasin B (Fowler et al., 2012a,b; Whitwell et al., 2015). Ethyl acrylate was tested at
different concentrations up to 55% of cytotoxicity for 3 h followed by recovery and for 24 h without
recovery. The results showed increases of frequencies of micronucleated cells in rodent p53-deﬁcient
cell lines. Following treatment of human cell lines WIL2-NS (with mutated p53) and TK6 (with
wild-type p53) using the cytochalasin-blocked cytokinesis assay, the majority of concentrations tested
resulted in micronucleated cell frequencies similar to the control values, with single exceptions,
characterised by a marginal increase at intermediate concentrations.
Using an alternative protocol in the absence of cytochalasin B following treatment of WIL2-NS and
TK6 cells with ethyl acrylate, normal frequencies of mononucleated cells with MN were observed for all
concentrations including those inducing 53% and 66% cytotoxicity, respectively, fulﬁlling the criteria for
clear negative responses. In contrast, small but statistically signiﬁcant increases in MN frequency were
observed at the highest two concentrations analysed following treatment of L5178Y cells. Signiﬁcant
increases in caspase activity (greater than threefold over the vehicle control) associated with high level
of toxicity were observed in TK6 cells after treatment with ethyl acrylate, suggesting apoptosis as a
mechanism of induction of micronuclei frequencies (Fowler et al., 2012a,b; Whitwell et al., 2015).
Summary of in vivo data assessed in FGE.71
In vivo genotoxicity studies described below were considered in FGE.71 (EFSA CEF Panel, 2010a),
based on JECFA evaluation (2006) and are summarised in Appendix A, Table A.1.
Single oral doses of ethyl acrylate at concentrations up to 4% were administered to male F344 rats
(Morimoto et al., 1990). The forestomach exhibited oedema and inﬂammation, but no DNA damage
was detected by alkaline elution.
In an in vivo-in vitro assay for clastogenicity, C57BL/6 male mice were given ethyl acrylate at doses
of 0, 125, 250, 500 or 1,000 mg/kg bw by i.p. injection (Kligerman et al., 1991). Twenty-four hours
later, animals were sacriﬁced, splenocytes were isolated and concanavalin A was added to stimulate
cell division. In half cultures, bromodeoxyuridine was added for the analysis of CA in the ﬁrst division
cells, and SCE in the second division cells. In the remaining cultures, cytochalasin B was added for the
scoring of MN in binucleated cells. No signiﬁcant increase of CA and SCE was reported, while ethyl
acrylate did induce a statistically signiﬁcant increase of binucleated cells with MN (less than twofolds
with respect to the control value) only at the highest dose (1,000 mg/kg bw); according to the study
authors, this increase was apparently due to a relatively high response in one of ﬁve animals. The
highest dose tested in this study is ﬁvefold higher than the highest dose (200 mg/kg bw) used in the
carcinogenicity study by the National Toxicology Program (1986) (Kligerman et al., 1991).
Although an early report (Przybojewska et al., 1984) indicated that ethyl acrylate was genotoxic in a
standard MN test in mice, subsequent studies (Ashby et al., 1989; Kligerman et al., 1991; Hara et al.,
1994; Morita et al., 1997) conﬁrmed that ethyl acrylate exhibits no genotoxic potential in this assay. An
increase in the incidence of polychromatic erythrocytes (PCE) with MN was reported in bone marrow of
BALB/C male mice treated with ethyl acrylate at doses of 225–1,800 mg/kg bw by i.p. injection in two
doses separated by 24 h. A statistically signiﬁcant decrease of the ratio between PCEs and
normochromatic erythrocytes (NCEs) was observed in the same range of doses, indicating bone marrow
toxicity (Przybojewska et al., 1984). There was no evidence of increase in MN cells collected 24 h after
groups of six BDF1 male mice were given ethyl acrylate as a single or two doses at 0, 188, 375 or
750 mg/kg bw by oral gavage or when ethyl acrylate was administered as a single dose at 0, 375, 500
or 750 mg/kg bw by i.p. injection. A statistically signiﬁcant reduction of reticulocyte percent after
double oral gavage and i.p. administration at 750 mg/kg was reported (Hara et al., 1994). In another
MN test, groups of ﬁve male and ﬁve female C57BL/6 mice were given ethyl acrylate as a single i.p.
dose at 461 or 738 mg/kg bw and samples were collected at 24, 48 (738 mg/kg bw dose only) and
72 h (738 mg/kg bw dose only) (Ashby et al., 1989). In subsequent experiments, groups of 5–10 male
C57BL/6 and BALB/c mice were given ethyl acrylate at a dose of 738 or 812 mg/kg bw in two doses
administered by i.p. injection within 24 h, and erythrocytes were sampled at 30 h. In none of these
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experiments, there was any evidence of increase in MN PCE in bone marrow of mice (Ashby et al.,
1989). Negative results were obtained for MN induction when groups of six male BDF1 mice were given
ethyl acrylate either as a single oral dose (188, 375 or 750 mg/kg bw) or a single intraperitoneal dose
(188 or 375 mg/kg bw) and samples of bone marrow were collected after 24 h (Morita et al., 1997).
In an assay for mutagenicity in vivo in Drosophila melanogaster, there was no evidence of increase
in sex-linked recessive lethals in three successive broods obtained from Basc virgin females mated with
Canton-S wild-type males either injected with ethyl acrylate at a concentration of 20,000 mg/kg or fed
a solution containing ethyl acrylate at a concentration of 40,000 mg/kg for 3 days. In a second
experiment, there was no evidence of mutagenicity when D. melanogaster were fed a solution
containing ethyl acrylate at a concentration of 18,000 or 20,000 mg/kg (Valencia et al., 1985).
In vivo data not previously considered
No new data are available.
Conclusions on genotoxicity
Overall, the Panel considered that based on the available data, which covers all relevant genetic
endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations), there is no
concern with respect to genotoxicity of ethyl acrylate.
3.6.3. Chronic toxicity and carcinogenicity
Carcinogenesis studies of ethyl acrylate was performed by NTP in B6C3F1 mice and F344/N rats
given the test compound in corn oil by gavage at doses of 100 and 200 mg/kg bw per day, 5 days per
week, for 103 weeks (NTP, 1986). There was no evidence of toxicity at any other sites than the
forestomach. A dose-related increase in the incidences of hyperkeratosis, hyperplasia and inﬂammation
of the forestomach were reported in both sexes and both species, in addition to a statistically
signiﬁcant positive trend in the incidence of squamous cell carcinoma and papilloma in the
forestomach. The incidence of tumours in the forestomach was higher in rats than in mice, which was
explained by a twofold higher concentration of ethyl acrylate in the gavage solution for rats than for
mice, in the 2-year study. Statistically signiﬁcant negative trends were reported for several tumours,
such as hepatocellular carcinoma, follicular cell tumour of the thyroid and lymphocytic lymphoma in
male mice. The conclusions from NTP (1986) were ‘Under the conditions of these studies, ethyl
acrylate was carcinogenic for the forestomach of F344/N rats and B6C3F1 mice, causing squamous cell
carcinomas in male rats and male mice, and squamous cell papillomas or carcinomas (combined) in
male and female rats and mice. Evidence for carcinogenicity was greater in males than in females.
Ethyl acrylate also caused irritation of the forestomach mucosa in male and female rats and mice’.
This conclusion was later modiﬁed (NTP, 1998), with the following recommendation ‘It is
recommended that ethyl acrylate be delisted from the Report on Carcinogens because the forestomach
tumors, induced in animal studies, were seen only when the chemical was administered by gavage at
high concentrations of ethyl acrylate, that induced marked local irritation and cellular proliferation and
because signiﬁcant chronic human exposure to high concentrations of ethyl acrylate monomer is unlikely’.
Ghanayem et al. (1993, 1994) studied the time required for sustained forestomach hyperplasia to
produce neoplastic lesions in F344 rats administered ethyl acrylate at 200 mg/kg bw per day, 5 days
per week, by gavage for 6 or 12 months. The increase in epithelial hyperplasia of the forestomach
sustained as long as the exposure continued. However, the hyperplasia regressed and no neoplasms
developed, when exposure was stopped after 6 months and the animals were allowed to recover until
they were sacriﬁced at 24 months of age. In contrast, forestomach squamous cell carcinoma
developed in rats treated for 12 months and allowed to recover for 9 months.
Acrylic acid, a metabolite of ethyl acrylate, was given to Wistar rats during 12 months in drinking
water, containing 120, 800, 2,000 or 5,000 mg/L, providing doses of about 9, 61, 140 and 331 mg/kg
bw per day, according to the authors (Hellwig et al., 1993). The two highest doses led to reduced
consumption of drinking water, indicating palatability problems. There were no indications of systemic
toxicity or carcinogenicity. Another study was performed in rats for 26 (males) and 29 (females)
months with drinking water concentrations of 120, 400 or 1,200 mg/L, providing doses of 8, 27 or
78 mg/kg bw per day. There were no indications of toxic changes or carcinogenic potential.
Overall, increases in forestomach squamous cell papilloma and carcinoma were reported in rats and
mice, when ethyl acrylate was administered via gavage. The neoplasms were preceded by extreme
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sustained irritation of the epithelium, which was reversible when exposure was stopped after 6 months
but not after 12 months. There was no evidence of systemic toxicity.
3.6.4. Discussion
The NTP carcinogenicity studies from 1986 concluded that ethyl acrylate administered by gavage
was carcinogenic for the forestomach of mice and rats due to increases in forestomach squamous cell
papilloma and carcinoma. The lesions were related to the concentration of ethyl acrylate in dosing
solutions. Severe irritation of the forestomach was seen after single oral administration of ethyl
acrylate. Hyperkeratosis, inﬂammation and hyperplasia of the forestomach were observed in
subchronic and 2-year gavage studies. There were no gastric lesions after parenteral administration
and no evidence of systemic toxicity in any of the studies. The Panel considered the observed local
forestomach lesions to be a consequence of the known irritating properties of ethyl acrylate.
The conclusion on carcinogenicity of ethyl acrylate from the NTP studies was revised in 1998, when
NTP recommended ethyl acrylate to be ‘delisted from the Report on Carcinogens because the
forestomach tumors, induced in animal studies, were seen only when the chemical was administered
by gavage at high concentrations of ethyl acrylate, that induced marked local irritation and cellular
proliferation and because signiﬁcant chronic human exposure to high concentrations of ethyl acrylate
monomer is unlikely’. This conclusion was supported by Williams and Iatropoulos (2009), who further
emphasised that the route and rate of ethyl acrylate exposure in rodents for forestomach neoplasia
are not relevant to humans, since humans do not have forestomach and are not exposed to ethyl
acrylate by oral bolus.
Based on experimental data (publications up to 1993) in rodents showing lesions and carcinoma of
forestomach, IARC (1999a) classiﬁed ethyl acrylate as possibly carcinogenic to humans (Group 2B). It
should be noted, that IARC monographs are intended to be hazard evaluations, that is to identify
whether a substance can be associated with the development of cancer, regardless of the dose or
exposure conditions at which an increased risk occur (Goodman and Lynch, 2017). In the mechanistic
considerations, IARC (1999a) noted that ethyl acrylate was clastogenic in vitro, but not in vivo.
The predictive value of rodent forestomach tumours in evaluating carcinogenic risks to humans was
discussed by IARC (1999b), which considered in particular exposure conditions and tissue speciﬁcity.
Exposure conditions should be considered, especially if oral gavage is used, because it can result in high
local concentration of the test substance in the forestomach and prolonged exposure of the epithelial
tissue. ‘Agents that produce tumors in rodent forestomach only after prolonged exposure through non-
DNA reactive mechanisms, may be less relevant to humans because human exposure would have to
overcome time-integrated dose thresholds to result in a carcinogenic response’ (IARC, 1999b).
In the present safety evaluation, genotoxicity of ethyl acrylate was assessed from all available data,
both previously assessed and previously not considered. Ethyl acrylate was negative in bacterial reverse
mutation assays. Ethyl acrylate resulted positive when tested in some in vitro assays for gene mutation
and CA in mammalian cells, however, in in vivo studies no genotoxicity effects were observed as also
reported for other acrylates (Johannsen et al., 2008). Therefore, based on the available data, which
covers all relevant genetic endpoints (i.e. gene mutations, structural and numerical chromosomal
aberrations), the Panel considers that there is no concern with respect to genotoxicity of ethyl acrylate.
The Panel agrees with the NTP re-evaluation (1998) and considers that the forestomach squamous
cell papilloma and carcinoma are preceded by extreme sustained irritation of the epithelium, which is
reversible when exposure is stopped after 6 months but not after 12 months. No lesions are observed
in the glandular stomach. Moreover, in short-term, subchronic and chronic toxicity studies, there was
no evidence of systemic toxicity.
The initiating events for the effects in the forestomach involve depletion of NPSH, which was observed
in the forestomach at gavage doses >100 mg/kg bw per day, while no signiﬁcant depletion was seen after
administration via drinking water at 200–4,000 mg/L (Frederick et al., 1990). The depletion of NPSH in
the rat forestomach was related to the histopathology observed at relatively high doses. At 10 mg/kg bw
and less, no signiﬁcant NPSH depletion and no histopathological ﬁndings were reported.
The estimated chronic dietary exposure of ethyl acrylate in adults and children were 60 and
150 lg/kg bw per day, respectively, calculated by the APET approach, with minimal contribution from
natural occurring ﬂavour in food. Maximum exposure from FCM may be up to 100 lg/kg bw per day.
The Panel considers that the forestomach tumours, observed in rodents, are not a relevant
toxicological endpoint to humans since they are not exposed to ethyl acrylate by oral bolus.
Furthermore, there is an absence of correlation between forestomach in rats and oesophageal lesions
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in humans, as reported in the reviews by Wester and Kroes (1988) and Proctor et al. (2007). The
Panel considers the effects of ethyl acrylate in the forestomach to be local and dependent on the
concentration of ethyl acrylate. The concentration and exposure time, which induce the irritating effect
in the forestomach would not be reached by exposure to ethyl acrylate via the use as a ﬂavouring.
Consequently, the Panel considers that the calculated chronic dietary exposure in adults and children
would not be of safety concern.
4. Conclusions
The Panel concluded that ethyl acrylate is not genotoxic in vivo and that carcinogenic effects
observed in rodent studies are not relevant to humans. Therefore, the Panel concluded that there is no
safety concern for the use of ethyl acrylate as a ﬂavouring substance in food, under the intended
conditions of use.
5. Recommendations
The Panel takes note of other potential sources of dietary exposure such as from FCM. Exposure
from plastic FCM could be up to the temporary TDI of 100 lg/kg bw per day, bringing the potential
exposure from both plastic and ﬂavouring above this TDI. The Commission may wish to take this into
account.
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Abbreviations
APET added portions exposure technique
bw body weight
CA chromosomal aberrations
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHL Chinese hamster lung (cells)
CHO Chinese hamster ovary (cells)
CoE Council of Europe
FAO Food and Agriculture Organization of the United Nations
FCM food contact materials
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GSH glutathione
IARC International Agency for Research on Cancer
ID Identity
IR infrared spectroscopy
i.p. intraperitoneal
JECFA The Joint FAO/WHO Expert Committee on Food Additives
MN micronuclei
MSDI Maximised Survey-derived Daily Intake
NCE normochromatic erythrocyte
NOAEL no observed adverse effect level
NPSH non-protein sulfhydryl
NTP National Toxicology Program
OECD Organisation for Economic Cooperation and Development
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PCE polychromatic erythrocytes
SCE sister chromatid exchanges
SCF Scientiﬁc Committee on Food
SML speciﬁc migration limit
SPET single portion exposure technique
TDI tolerable daily intake
WHO World Health Organization
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Appendix A – Genotoxicity data evaluated in FGE.71
Table A.1: Genotoxicity data on ethyl acrylate [FL-no: 09.037] evaluated by JECFA (2006) and considered by EFSA in FGE.71 (2010)
Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
In vitro
Ethyl acrylate
09.037
1351
Reverse
mutation
Salmonella Typhimurium
TA98, TA100,
TA1535, TA1537 and
TA1538
30–2,000 lg/plate Negative(a) Waegemaekers and
Bensink (1984)
Reliable with the following restriction:
the study complied with current
recommendations with the exception
that tester strains TA102 or E. coli
WP2uvrA were not used
S. Typhimurium TA97,
TA98,
TA100 and TA1535
33–3,333 lg/plate Negative(a),(b) Zeiger et al. (1992) Reliable with the following restriction:
the study complied with current
recommendations with the exception
that tester strains TA102 or E. coli
WP2uvrA were not used
S. Typhimurium TA98,
TA100,
TA1535 and TA1537
100–10,000 lg/plate Equivocal(a),(b),(c) Haworth et al. (1983) Reliable with the following restriction:
the study complied with current
recommendations with the exception
that tester strains TA102 or E. coli
WP2uvrA were not used
S. Typhimurium TA98,
TA100 and TA1537
NR Negative(a),(b) Ishidate et al. (1981) No data reported
S. Typhimurium ≤ 10,000 lg/plate Negative(a) Tennant et al. (1987) Reliable with restrictions (review
paper without detailed results)
Mitotic
chromosomal
recombination
Saccharomyces
cerevisiae D61.M
≤ 1,095 lg/mL Negative(d),(e) Zimmermann and
Mohr (1992)
Reliable. Endpoint of low relevance,
no OECD guideline available
S. cerevisiae D61.M ≤ 1,095 lg/mL Positive(d)
S. cerevisiae D61.M ≤ 914 lg/mL Negative(e)
Forward
mutation
Mouse lymphoma L5178Y
Tk+/ cells
20 lg/mL Positive(f) Tennant et al. (1987) Reliable with restrictions (review
paper without detailed results)
Mouse lymphoma L5178Y
Tk+/ cells
10, 15, 20, 25, 27.5,
30, 32.5, 35, 40 or
50 lg/mL
Positive(f),(g) Ciaccio et al. (1998) Reliable without restrictions. Study in
line with OECD guideline No. 490
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Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
Mouse lymphoma L5178Y
Tk+/ cells
20, 25, 30 or
37.5 lg/mL
Positive(f),(h) Moore et al. (1988) Reliable without restrictions. Study in
line with OECD guideline No. 490
Large majority of mutants are small-
colony mutants
Mouse lymphoma L5178Y
Tk+/ cells
2.5–40 lg/mL Positive(f),(i) McGregor et al. (1988) Reliable without restrictions. Study in
line with OECD guideline No. 490
Positive only at highest dose.
Equivocal using the ‘global evaluation
factor approach’
Chromosomal
aberration
Chinese hamster ovary
cells
299 lg/mL
<29.9 lg/mL
Positive(j)
Negative(f),(h)
Loveday et al. (1990) Reliable without restrictions Study in
line with OECD guideline No. 473
Mouse lymphoma L5178Y
Tk+/ cells
20, 25, 30 or
37.5 lg/mL
Positive(f),(h) Moore et al. (1988) Reliable without restrictions Study in
line with OECD guideline No. 473
Chinese hamster lung
cells
0.0098 mg/mL(k)
(9.8 lg/mL)
Positive(a) Ishidate et al. (1981) Reliable with restrictions (review
paper without detailed results)
Chinese hamster ovary
cells
299 lg/mL Positive(j)
Negative(f)
Tennant et al. (1987) Reliable with restrictions (review
paper without detailed results)
Sister chromatid
exchange
Chinese hamster ovary
cells
150 lg/mL Positive(j)
Negative(f)
Reliable with restrictions (review
paper without detailed results)
OECD guideline was withdrawn
Chinese hamster ovary
cells
150 lg/mL
<5 lg/mL
Weak positive(j)
Negative(f),(h)
Loveday et al. (1990) Reliable without restrictions. The
endpoint has low relevance (OECD
guideline was withdrawn)
Mouse lymphoma L5178Y
Tk+/ cells
20.0–37.5 lg/mL Positive(f),(h) Moore et al. (1988) Reliable without restrictions. The
endpoint has low relevance (OECD
guideline was withdrawn)
Mouse splenocytes 10–80 lg/mL Negative(l) Kligerman et al. (1991) Reliable without restrictions. The
endpoint has low relevance (OECD
guideline was withdrawn)
1–20 lg/mL Negative(m)
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Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
In vivo
Ethyl acrylate
09.037
1351
Sister chromatid
exchange
Male C57BL/6 mice 125, 250, 500 or
1,000 mg/kg(n)
Negative Kligerman et al. (1991) In vivo-vitro study (animals were
exposed, splenocytes were isolated
and cultured in vitro) (OECD guideline
was withdrawn)
Chromosomal
aberration
Male C57BL/6 mice 125, 250, 500 or
1,000 mg/kg(n)
Negative In vivo-vitro study
(animals were exposed, splenocytes
were isolated and cultured in vitro)
this experimental protocol is not
described in OECD guideline No. 475
Micronucleus
formation
Male C57BL/6 mice 125, 250, 500 or
1,000 mg/kg(n)
Negative(q) Kligerman et al. (1991) In vivo-vitro study (animals were
exposed, splenocytes were isolated
and cultured in vitro) This
experimental protocol is not described
in OECD guideline No. 474
Male BALB/c mice 225–1,800 mg/kg(r) Positive Przybojewska et al.
(1984)
Reliable with restrictions: 4 animals/
group were treated. Highest dose
(1,800 mg/kg) was toxic. 2/4 animals
died
Male and female C57BL/6
mice
461(n),(s) or
738 mg/kg(n),(t)
Negative Ashby et al. (1989) Reliable with restrictions (review
paper)
Male BALB/c mice 812 mg/kg(u) Negative
Male C57BL/6 mice 738 mg/kg(u) Negative
Male BDF1 mice 188, 375 or
750 mg/kg(s),(v)
Negative Hara et al. (1994) Reliable with restrictions (poor
reporting)
188, 375 or
750 mg/kg(w)
Negative(x)
375, 500 or
750 mg/kg(n),(s)
Negative(x)
Male BDF1 mice 188, 375, 750 or
1,000 mg/kg(n),(s),(v)
Negative(y) Morita et al. (1997) Reliable with restrictions Basically
following the OECD guidelines.
Except that no data were reported on
PCE/NCE ratio
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Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
DNA alkaline
elution
Male F344 rat
forestomach squamous
epithelium
0.1–4.0%
(50–2,000 mg/kg)(v)
Negative Morimoto et al. (1990) Reliable without restrictions. No OECD
guidelines are available
Sex-linked
recessive lethal
mutations
Drosophila melanogaster 20,000 mg/kg Negative(o) Valencia et al. (1985) Reliable without restrictions. Low
relevance of target organism. OECD
guideline withdrawn
Micronucleus
formation
D. melanogaster 18,000; 20,000 or
40,000 mg/kg
Negative(p) Valencia et al. (1985) Reliable without restrictions. Low
relevance of target organism. No
OECD guideline available
OECD: Organisation for Economic Cooperation and Development; PCE: polychromatic erythrocyte; NCE: normochromatic erythrocyte.
(a): With and without metabolic activation.
(b): Pre-incubation method.
(c): The Ames tests were performed by two different laboratories, resulting in positive and negative results in the ﬁrst and second experiments, respectively. The authors considered the results
from the conﬁrmation (second) experiment to be more deﬁnitive.
(d): Cold shock regimen (i.e. 4-h incubation at 28°C, followed by a 16-h storage in an ice bath and a 4-h incubation at 28°C).
(e): Uninterrupted 16-h incubation at 28°C.
(f): Without metabolic activation.
(g): Relative cell growth was 20% and 13%, respectively, at the two highest doses tested (40 and 50 lg/mL, respectively).
(h): Cytotoxicity was observed at the highest dose tested.
(i): Statistically signiﬁcant increases in mutant fraction were observed at doses of 20 and 40 lg/mL.
(j): With metabolic activation.
(k): Dose at which chromosomal aberrations were detected in 20% of metaphase cells.
(l): Exposure during the Go phase of the cell cycle. Cytotoxicity was observed at doses of >30 lg/mL.
(m): Exposure during the G-S phase of the cell cycle. Cytotoxicity was observed at doses of >10 lg/mL.
(n): Administered intraperitoneally.
(o): Injection experiment.
(p): Feeding experiment.
(q): A slight but signiﬁcant increases in the frequency of micronucleus formation was observed at the highest dose tested (1000 mg/kg), which was thought to be due to an elevated frequency in
one of the four treated mice.
(r): Administered intraperitoneally in two doses within 24 h.
(s): Assessment of bone marrow for formation of micronuclei 24 h after dosing.
(t): Assessment of bone marrow for formation of micronuclei 24, 48 or 72 h after dosing.
(u): Administered intraperitoneally at 0 and 24 h, followed by assessment of bone marrow for formation of micronuclei 6 h later.
(v): Administered orally.
(w): Administered orally twice within 24-h.
(x): A signiﬁcant decrease in the reticulocyte ratio was observed at the highest dose tested compared with vehicle controls.
(y): Mortality was observed at the highest dose tested (1,000 mg/kg).
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Appendix B – Previously not considered genotoxicity data
Table B.1: In vitro genotoxicity studies on ethyl acrylate [FL-no: 09.037]
Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
Ethyl acrylate
09.037
1351
Ames test Salmonella
Typhimurium TA102
Up to 5,000
lg/plate
Negative Kirkland et al.
(2016)
Reliable without restrictions. The study complies with
OECD Test Guideline 471
S. Typhimurium strain
YG7108,
transformed with the
plasmid pin3ERb5
Up to 2,000
lg/plate
Negative Emmert et al.
(2006)
Reliable without restrictions. The study was designed
to test the compound in a metabolically competent
S. Typhimurium strain
Micronucleus
Assay
p53-deﬁcient rodent
cell lines:
V79
0–20(b),(c);
0–8(b),(d) lg/mL
Positive(b),(c),(d) Fowler et al.
(2012a)
Reliable without restrictions In the short-term
treatment, MN were induced at concentrations of
ethyl acrylate resulting in cytotoxicity of 50–60%
The study was designed to investigate the different
results in the MN assay depending on the cell line
CHO 0–32(b),(c);
0–12(b),(d) lg/mL
Positive(b),(c);
Negative(b),(d)
CHL 0–40(b),(c);
0–14(b),(d) lg/mL
Positive(b),(c) and (b),(d)
p53-competent human
cells:
peripheral blood
lymphocytes
0–50(b),(c);
0–10.4(b),(d) lg/mL
Positive(b),(c);
Negative(b),(d)
TK6 human
lymphoblastoid cells
0–28(b),(c);
0–12(b),(d) lg/mL
Positive(b),(c);
Negative(b),(d)
HepG2 0–96(b),(c);
0–150(b),(d) lg/mL
Equivocal(b),(c)
Negative(b),(d)
p53-mutant mouse
lymphoma L5178Y
0–18 lg/mL Equivocal in the
absence of
cytochalasin B
Whitwell et al.
(2015)
Reliable without restrictions. The study was designed
to investigate the possible role of p53 and apoptosis
in the micronuclei induction
p53-competent human
lymphoblastoid TK6
0–10 lg/mL Equivocal with both
human cell linesin the
presence of
cytochalasin B
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Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
p53-mutant human
WIL2-NS cells
0–9 lg/mL Negative with both
human cell lines in the
absence of
cytochalasin B
OECD: Organisation for Economic Cooperation and Development.
(a): With metabolic activation.
(b): Without metabolic activation.
(c): 3 h treatment + 21 h recovery.
(d): 24 h treatment + 0 h recovery.
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Appendix C – Exposure
Calculation of the Dietary Exposure - APET
Chronic Dietary Exposure – ‘Added Portions Exposure Technique’ (APET)5
The chronic APET calculations are based on the normal combined occurrence level by adding the
highest contributing portion of food and highest contributing portion of beverages (either among soft
drinks or alcoholic beverages). APET for children is calculated by adding the highest contributing
portion of food and highest contributing portion of beverages (among soft drinks). Furthermore, in the
APET calculation for children, the portion sizes listed in Table 8 is adjusted by a factor 0.63 to take into
account the smaller portion sizes consumed by the child.
Adults (‘Added Portions Exposure Technique’ [APET])
On the basis of normal occurrence level from the added ﬂavouring only
Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 2,120 lg/adult per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of 1,425 lg/adult
per day.
The total APET will be 3,545 lg/adult per day corresponding to 59.1 lg/kg bw per day for a 60-kg
person.
Children (3-year-old child of 15 kg body weight)
Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 2,120 x 0.63 = 1,335 lg/child per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of
1,425 9 0.63 = 898 lg/child per day.
The total APET will be 2,233 lg/child per day corresponding to 149 lg/kg bw per day for a 15-kg
child.
Conclusion
The higher of the two values among adults and children, expressed per kg/bw per day, should be
used as the basis for the safety evaluation of the candidate substance, i.e. the value of 150 lg/kg bw
per day for a 15-kg child should be compared to the appropriate no observed adverse effect level
(NOAEL) for the candidate substance.
Combined Dietary Exposure
This is an estimate of total dietary exposure deriving from both the addition of the ﬂavouring
substance to foods and beverages and other dietary sources. To estimate the APET for combined
dietary exposure, the occurrence of the substance in grapes and vanilla was also taken into account in
the estimation.
Adults (‘Added Portions Exposure Technique’ [APET])
Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 2,120 lg/adult per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of 1,425 lg/adult
per day.
The total APET will be 3,545 lg/adult per day corresponding to 59.1 lg/kg bw per day for a 60-kg
person.
Children (3-year-old child of 15 kg body weight)
Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 2,120 9 0.63 = 1,335 lg/child per day.
5 The APET has been calculated based on the occurrence levels in the food subcategories reported in the above table, with the
exclusion of categories 13.2 (complementary foods for infants and young children).
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Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of
1,425 9 0.63 = 898 lg/child per day.
The total APET will be 2,233 lg/child per day corresponding to 149 lg/kg bw per day for a 15-kg
child.
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Table C.1: Normal and maximum occurrence levels for reﬁned categories of foods and beverages
Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined
occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
01.1 Milk and dairy-based drinks 200 10.6 15.2 10.6 15.2
01.2 Fermented and renneted milk products (plain), excluding food
category 01.1.2 (dairy-based drinks)
200 10.6 15.2 10.6 15.2
01.3 Condensed milk and analogues (plain) 70 10.6 15.2 10.6 15.2
01.4 Cream (plain) and the like 15 10.6 15.2 10.6 15.2
01.5 Milk powder and cream powder and powder
analogues (plain)
30 10.6 15.2 10.6 15.2
01.6 Cheese and analogues 40 10.6 15.2 10.6 15.2
01.7 Dairy-based desserts (e.g. pudding, fruit or ﬂavoured yoghurt) 125 10.6 15.2 10.6 15.2
01.8 Whey and whey products, excluding whey cheeses 200 10.6 15.2 10.6 15.2
02.1 Fats and oils essentially free from water 15
02.2 Fat emulsions mainly of type water-in-oil 15
02.3 Fat emulsions mainly of type water-in-oil, including mixed
and/or ﬂavoured products based on fat emulsions
15
02.4 Fat-based desserts excluding dairy-based dessert products of
category 1.7
50
03.0 Edible ices, including sherbet and sorbet 50
04.1.1 Fresh fruit 140 0.1 0.1 0.1 0.1
04.1.2 Processed fruit 125 0.1 0.1 0.1 0.1
04.1.2.5 Jams, jellies, marmalades 30
04.2.1 Fresh vegetables (including mushrooms and fungi, roots and tubers,
pulses and legumes, and aloe vera), seaweed, and nut and seed
200
04.2.2 Processed vegetables (including mushrooms and fungi, roots and tubers,
pulses and legumes, and aloe vera), seaweed, and nut and
seed purees and spreads (e.g. peanut butter) and nuts and seeds
200
04.2.2.5 Vegetables (including mushrooms and fungi, roots and tubers,
pulses and legumes, and aloe vera), seaweed, and nut and seed
purees and spreads (e.g. peanut butter)
30
05.1 Cocoa products and chocolate products, including imitations and
chocolate substitutes
40 10.14 13.3 10.14 13.3
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined
occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
05.1.3 Cocoa-based spreads, including ﬁllings 30 10.14 13.3 10.14 13.3
05.2 Confectionery, including hard and soft candy, nougats, etc., other
than 05.1, 05.3 and 05.4
30 10.14 13.3 10.14 13.3
05.3 Chewing gum 3 0.07 0.11 0.07 0.11
05.4 Decorations (e.g. for ﬁne bakery wares), toppings (non-fruit) and
sweet sauces
35 10.14 13.3 10.14 13.3
06.1 Whole, broken or ﬂaked grain, including rice 200 6.77 10.84 6.77 10.84
06.2 Flours and starches (including soya bean powder) 30 6.77 10.84 6.77 10.84
06.3 Breakfast cereals, including rolled oats 30 6.77 10.84 6.77 10.84
06.4 Pastas and noodles and like products (e.g. rice paper, rice vermicelli,
soya bean pastas and noodles)
200 6.77 10.84 6.77 10.84
06.5 Cereal- and starch-based desserts (e.g. rice pudding, tapioca
pudding)
200 6.77 10.84 6.77 10.84
06.6 Batters (e.g. for breading or batters for ﬁsh or poultry) 30 6.77 10.84 6.77 10.84
06.7 Pre-cooked or processed rice products, including rice cakes
(Oriental type only)
200 6.77 10.84 6.77 10.84
06.8 Soya bean products (excluding soya bean products of food
category 12.9 and fermented soya bean products of food
category 12.10)
100 6.77 10.84 6.77 10.84
07.1 Bread and ordinary bakery wares 50 11.75 13.76 11.75 13.76
07.2 Fine bakery wares (sweet, salty, savoury) and mixes 80 11.75 13.76 11.75 13.76
08.1 Fresh meat, poultry and game 200 0.1 0.1 0.1 0.1
08.2 Processed meat, poultry and game products in whole pieces or cuts 100 0.1 0.1 0.1 0.1
08.3 Processed comminute meat, poultry and game products 100 0.1 0.1 0.1 0.1
08.4 Edible casings (e.g. sausage casings) 1 0.1 0.1 0.1 0.1
09.1.1 Fresh ﬁsh 200
09.1.2 Fresh molluscs, crustaceans and echinoderms 200
09.2 Processed ﬁsh and ﬁsh products, including molluscs, crustaceans
and echinoderms
100
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined
occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
09.3 Semi-preserved ﬁsh and ﬁsh products, including molluscs,
crustaceans and echinoderms
100
09.4 Fully preserved, including canned or fermented, ﬁsh and ﬁsh
products, including molluscs, crustaceans and echinoderms
100
10.1 Fresh eggs 100
10.2 Egg products 100
10.3 Preserved eggs, including alkaline. salted and canned eggs 100
10.4 Egg-based desserts (e.g. custard) 125
11.1 Reﬁned and raw sugar 10
11.2 Brown sugar excluding products of food category 11.1 10
11.3 Sugar solutions and syrups, and (partially) inverted sugars, including
molasses and treacle, excluding products of food category 11.1.3
(soft white sugar, soft brown sugar, glucose syrup, dried glucose
syrup, raw cane sugar)
30
11.4 Other sugars and syrups (e.g. xylose, maple syrup, sugar toppings) 30
11.5 Honey 15
11.6 Table-top sweeteners, including those containing high-intensity
sweeteners
1
12.1 Salt and salt substitutes 1
12.10 Protein products other than from soybeans 15
12.2 Herbs, spices, seasonings and condiments (e.g. seasoning for
instant noodles)
1
12.3 Vinegars 15
12.4 Mustards 15
12.5 Soups and broths 200
12.6 Sauces and like products 30
12.7.a Salads 120 g (e.g. macaroni salad, potato salad) excluding
cocoa- and nut-based spreads of food categories
120
12.7.b Sandwich spreads (20 g), excluding cocoa- and nut-based spreads of
food categories
20
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined
occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
12.8 Yeast and like products 1
12.9 Soybean-based seasonings and condiments 15
12.9.1 Fermented soya bean products (e.g. miso) 40
12.9.2 Soybean sauce 15
12.9.3 Fermented soybean sauce 15
13.2.a Complementary foods for infants and young children: Dry instant
cereals (with or without milk), including pasta
110
13.2.b Complementary foods for infants and young children:
Meat-based or ﬁsh-based dinner
170
13.2.c Complementary foods for infants and young children:
Dairy-based dessert
110
13.2.d Complementary foods for infants and young children:
Vegetables, potatoes, broth, soups, pulses
170
13.2.e Complementary foods for infants and young children:
Biscuits and cookies
20
13.2.f Complementary foods for infants and young children: Fruit puree 110
13.2.g Complementary foods for infants and young children: Fruit juice 120
13.2.h Milk for young children 200
13.3 Dietetic foods intended for special medical purposes (excluding food
products of category 13.1 ‘Infant formulae, follow-up formulae
and other formulae for special medical purposes for infants’)
200
13.4 Dietetic formulae for slimming purposes and weight reduction 200
13.5 Dietetic foods (e.g. supplementary foods for dietary use), excluding
products of food categories 13.1 (Infant formulae, follow-up formulae
and other formulae for special medical purposes for infants),
13.2–13.4 and 13.6
200
13.6 Food supplements 5
14.1 Other non-alcoholic (‘soft’) beverages (expressed as liquid) 300 4.75 8.75 4.75 8.75
14.2.1 Beer and malt beverages 300 0.38 1 0.38 1
14.2.2 Cider and perry 300 0.38 1 0.38 1
Safety of ethyl acrylate
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2017;15(11):5012
Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined
occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
14.2.3 Grape wines 150 0.38 1 0.38 1
14.2.4 Wines (other than grape) 150 0.38 1 0.38 1
14.2.5 Mead 150 0.38 1 0.38 1
14.2.6 Distilled spirituous beverages containing more than 15% alcohol 30 0.38 1 0.38 1
14.2.7 Aromatised alcoholic beverages (e.g. beer, wine and spirituous
cooler-type beverages, low alcoholic refreshers)
300 0.38 1 0.38 1
15.1 Snacks, potato-, cereal-, ﬂour- or starch-based (from roots and
tubers, pulses and legumes)
30
15.2 Processed nuts, including coated nuts and nut mixtures
(with e.g. dried fruit)
30
15.3 Snacks – ﬁsh-based 30
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods
that could not be placed in categories 01–15
300
(a): Most of the categories reported are the sub-categories of Codex GSFA (General Standard for Food Additives, available at http://www.codexalimentarius.net/gsfaonline/CXS_192e.pdf), used by
the JECFA in the SPET technique (FAO/WHO, 2008). In the case of category 13.2 (complementary foods for infants and young children), further reﬁned categories have been created so that a
speciﬁc assessment of dietary exposure can be performed in young children.
(b): For Adults. In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the instructions reported on the product
label or one of the standard dilution factors established by the JECFA (FAO/WHO, 2008):
 1/25 for powder used to prepare water-based drinks such as coffee, containing no additional ingredients,
 1/10 for powder used to prepare water-based drinks containing additional ingredients such as sugars (ice tea, squashes, etc.),
 1/7 for powder used to prepare milk, soups and puddings,
 1/3 for condensed milk.
(c): As natural constituent and/or developed during the processing and/or as carry over resulting from their use in animal feed.
(d): In order to estimate normal values in each category, only foods and beverages in which the substance is present in signiﬁcant amount will be considered (e.g. for the category ‘Fresh fruit’
04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where the ﬂavouring substance is known to occur).
(e): As added ﬂavouring or from other sources. The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels from
added use to that from other sources or by expert judgement based on the likelihood of their concomitant presence. This will be done both for normal use levels and for maximum use levels.
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